CUSIP: 16961L106
Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
61,514,270
-
Share change
-
+3,345,144
-
Total reported value
-
$1,422,343,945
-
Put/Call ratio
-
3.3%
-
Price per share
-
$23.15
-
Number of holders
-
156
-
Value change
-
+$75,145,307
-
Number of buys
-
76
-
Number of sells
-
63
Quarterly Holders Quick Answers
What is CUSIP 16961L106?
CUSIP 16961L106 identifies KDNY - CHINOOK THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2023
-
Previous quarter:
Q4 2022
Recent filing periods for CUSIP 16961L106:
Institutional Holders of CHINOOK THERAPEUTICS INC - COM (KDNY) as of Q1 2023
As of 31 Mar 2023,
CHINOOK THERAPEUTICS INC - COM (KDNY) was held by
156 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
61,514,270 shares.
The largest 10 holders included
Samsara BioCapital, LLC, Frazier Life Sciences Management, L.P., BlackRock Inc., Deep Track Capital, LP, VANGUARD GROUP INC, STATE STREET CORP, Octagon Capital Advisors LP, ORBIMED ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., and SUVRETTA CAPITAL MANAGEMENT, LLC.
This page lists
156
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.